Cart
sales@molnova.com
Palivizumab
Palivizumab
Catalog No. M36768
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
| Size | Price / USD | Stock | Quantity |
| 5MG | 549 | In Stock |
|
| 10MG | 785 | In Stock |
|
| 25MG | 1159 | In Stock |
|
| 50MG | 1535 | In Stock |
|
| 100MG | 2074 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePalivizumab
-
Brief Description
-
Description
-
Storage
-
NoteResearch use only, not for human use.
-
Reference1. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998 Sep;102(3 Pt 1):531-7.?
molnova catalog
related products
-
ML116
A novel selective STAT3 inhibitor with IC50 of 4.2 uM.
-
NSC 370284
NSC 370284 is a small molecule that directly binds to and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo.
-
Pomstafib-2
The pivaloyloxymethyl ester prodrug of Stafib-2, which is a potent, selective STAT5b inhibitor with Ki of 9 nM.
